GUILFORD, Conn., April 27, 2021 (GLOBE NEWSWIRE) — InveniAI® LLC, a global leader in pioneering the application of Artificial Intelligence (AI) and Machine Learning (ML) to transform innovation across drug discovery and development, today announced a multi-target drug discovery collaboration with Shionogi & Co., Ltd., a global, research-driven pharmaceutical company.
Teams will work together by leveraging InveniAI's technology to identify, evaluate, and optimize novel targets for drug discovery. Shionogi will synthesize and develop compounds for targets identified by InveniAI and advance select programs into research and clinical development. InveniAI is eligible to receive up to $200 million per program for a combination of upfront payments, development and commercial milestones, and royalties.
The multi-year collaboration will combine InveniAI's AI platform, AlphaMeld®, to research and validate targets with Shionogi's expertise in developing and commercializing appropriate therapeutic modalities. Shionogi will be responsible for developing, manufacturing, and commercializing the candidates.
"Shionogi constantly strives to supply the best possible medicines to protect the health and wellbeing of the patients we serve, and we are delighted to further this mission through our collaboration with InveniAI. This collaboration allows us to use the power of AI to automate the early discovery phase by trawling vast datasets to identify targets, find candidate molecules, and predict favorable outcomes," said Ryuichi Kiyama, Ph.D., Executive Vice President, Senior Executive Officer, Head of Pharmaceutical Research Division.
"As we increasingly witness the transformational impact of AI applications in pharmaceutical development, we are excited to combine forces with Shionogi to apply an efficient data-driven approach to drug discovery. Our AI platform, AlphaMeld®, can comprehensively identify biological targets for a disease and align the best drug modalities while prioritizing both safety and efficacy," said Krishnan Nandabalan, Ph.D., President and CEO, InveniAI.